Shares of Radius Health Inc (NASDAQ:RDUS) have been given an average recommendation of “Hold” by the thirteen ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $55.25.
Several equities research analysts have commented on RDUS shares. JPMorgan Chase & Co. lowered their price target on shares of Radius Health from $70.00 to $60.00 and set an “overweight” rating on the stock in a report on Monday. Morgan Stanley initiated coverage on shares of Radius Health in a report on Monday, January 29th. They issued an “overweight” rating and a $57.00 price target on the stock. Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Monday, January 8th. Cantor Fitzgerald reissued a “buy” rating and set a $58.00 target price on shares of Radius Health in a research note on Friday, November 3rd. Finally, Citigroup initiated coverage on shares of Radius Health in a research note on Wednesday, December 6th. They set a “neutral” rating and a $30.00 target price on the stock.
In other news, major shareholder Growth N. V. Biotech bought 75,000 shares of the stock in a transaction dated Friday, February 9th. The shares were acquired at an average cost of $34.38 per share, with a total value of $2,578,500.00. Following the purchase, the insider now directly owns 5,773,799 shares in the company, valued at approximately $198,503,209.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 15.00% of the company’s stock.
Shares of Radius Health (NASDAQ:RDUS) opened at $36.42 on Tuesday. Radius Health has a 1-year low of $24.66 and a 1-year high of $49.16. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79. The company has a market cap of $1,567.85, a price-to-earnings ratio of -6.71 and a beta of 1.21.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.